Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8609384 | 0.80 | ALDH1A1 (0.40) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL10195453 | 0.73 | LMNA (0.40) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL23733143 | 0.70 | LMNA (0.34) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL2601688 | 0.69 | — | — | |
| SCHEMBL16091680 | 0.69 | ALDH1A1 (0.34) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL23733068 | 0.69 | ALDH1A1 (0.35) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL16091679 | 0.69 | LMNA (0.37) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL12107403 | 0.67 | LMNA (0.39) | LMNAADRA2CGSK3AGSK3BMGLL | |
| SCHEMBL11730000 | 0.67 | ATM (0.50) | ALDH1A1KDM4ELMNAL3MBTL1 | |
| SCHEMBL23733175 | 0.66 | KDM4E (0.33) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120213855-A1 | DOSAGE FORMS FOR WEAKLY IONIZABLE COMPOUNDS | CIMA LABS INC. (US) | 2012-08-23 | — | — | US | claimed |
| JP-2012500643-A | — | — | 2012-01-12 | — | — | JP | claimed |
| US-20110223251-A1 | BACTERIAL COMPOSITION | CHR-HANSEN A/S | 2011-09-15 | — | — | US | claimed |
| EP-2334302-A2 | DOSAGE FORMS FOR WEAKLY IONIZABLE COMPOUNDS | Cima Labs Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| EP-2318511-A1 | BACTERIAL COMPOSITION | Chr. Hansen A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| CN-101141949-B | New pharmaceutical compositions useful in the treatment of parkinson's disease | OREXO AB | 2010-12-08 | — | — | CN | claimed |
| WO-2010030667-A2 | DOSAGE FORMS FOR WEAKLY IONIZABLE COMPOUNDS | CIMA LABS INC. (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2010023248-A1 | Bacterial Composition | CHR. HANSEN A/S (DK) | 2010-03-04 | — | — | WO | claimed |
| US-20080193526-A1 | Pharmaceutical Compositions Useful in the Treatment of Pain | OREXO AB (SE) | 2008-08-14 | — | — | US | claimed |
| CN-101141949-A | New pharmaceutical compositions useful in the treatment of parkinson's disease | OREXO AB (SE) | 2008-03-12 | — | — | CN | claimed |
| EP-1863455-A1 | NEW PHARMACEUTICAL COMPOSITIONS USEFUL IN THE TREATMENT OF PARKINSON'S DISEASE | Orexo AB (SE) | 2007-12-12 | — | — | EP | claimed |
| WO-2006103417-A1 | NEW PHARMACEUTICAL COMPOSITIONS USEFUL IN THE TREATMENT OF PARKINSON'S DISEASE | OREXO AB (SE) | 2006-10-05 | — | — | WO | claimed |
| WO-2006078241-A1 | EFFERVESCENT AND EFFERVESCENT-DISPERSION COMPOSITIONS FOR MEDICAMENTS AND METHODS OF USE THEREOF | SERENE MEDICAL, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-20050074489-A1 | Effervescent and effervescent-dispersion compositions for medicaments and methods of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| US-20050031677-A1 | Sequential drug delivery systems | CIMA LABS INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20030232080-A1 | Sequential drug delivery systems | CIMA LABS INC. (US) | 2003-12-18 | — | — | US | claimed |
| CN-110590485-B | FSO 2 N 3 Use in the production of azido compounds | 中宏鑫投资控股(深圳)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-111417398-A | Glycan formulations for treating infections | 卡莱多生物科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-1151117-A | Binding of E-selectin, P-selectin or L-selectin to sialyl-Lewis(x) or sialyl-lewis(a) | TAXAS BIOTECHNOLOGY CORP (US) | 1997-06-04 | — | — | CN | disclosed |
| US-5525576-A | CARBOHYDRATES AND POLYHYDROXYCARBOXYLIC ACIDS OBTAINED BY THE OXIDATION OF A HULL-FREE PENTOSE-CONTAINING EXTRACT; ENHANCED ABSORPTION OF PLANT GROWTH REGULATORS, INSECTICIDES, FUNGICIDES AND PESTICIDES | MEDINA-VEGA LUIS R (US) | 1996-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213855-A1 | DOSAGE FORMS FOR WEAKLY IONIZABLE COMPOUNDS | ABCB11, CEL, SLC7A5 | ALDH1A1 2213/4885KDM4E 3774/4885SMN1; SMN2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.